Satellos Bioscience Inc
XTSX:MSCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Satellos Bioscience Inc
Cash & Cash Equivalents
Satellos Bioscience Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Satellos Bioscience Inc
XTSX:MSCL
|
Cash & Cash Equivalents
CA$1.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash & Cash Equivalents
CA$82.9m
|
CAGR 3-Years
61%
|
CAGR 5-Years
153%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash & Cash Equivalents
$80.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
30%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash & Cash Equivalents
$199.2m
|
CAGR 3-Years
52%
|
CAGR 5-Years
35%
|
CAGR 10-Years
13%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Cash & Cash Equivalents
CA$80.6m
|
CAGR 3-Years
48%
|
CAGR 5-Years
252%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Cash & Cash Equivalents
$50.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Satellos Bioscience Inc
Glance View
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-12-01. The firm is engaged in developing therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct dysregulated muscle stem-cell polarity, which balances replenishment of muscle stem cells and production of specialized tissue cells. The company uses MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders. The company also maintains two clinical stage products: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. iCo-008 provides treatment of the dermatological condition bullous pemphigoid (BP), atopic dermatitis, gastrointestinal conditions, and age-related macular degeneration (AMD). Oral Amphotericin B delivery system provides treatment of Visceral Leishmaniasis (VL).
See Also
What is Satellos Bioscience Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.9m
CAD
Based on the financial report for Dec 31, 2022, Satellos Bioscience Inc's Cash & Cash Equivalents amounts to 1.9m CAD.
What is Satellos Bioscience Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
11%
Over the last year, the Cash & Cash Equivalents growth was -61%. The average annual Cash & Cash Equivalents growth rates for Satellos Bioscience Inc have been 25% over the past three years , 11% over the past five years .
